Nine weeks versus 1 year adjuvant trastuzumab in combination with

trastuzumab  1 ยาพุ่งเป้า HER2 ที่ตัวรับ HER2 ที่ผิวเซลล์มะเร็ง แบ่งเป็น 2 ชนิด · Monoclonal antibody ออกฤทธิ์นอกเซลล์ ได้แก่ pertuzumab, trastuzumab ( Common side effects of pertuzumab and trastuzumab · Risk of infection · Bruising and bleeding · Anaemia · Effects on the heart

Cardiotoxicity Trastuzumab is a monoclonal antibody tyrosine kinase inhibitor that targets the HER2 receptor often over overexpressed or overactive in breast Key Message The ShortHER trial failed to demonstrate the non-inferiority of 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy The short

Trastuzumab, a humanized monoclonal antibody against the ectodomain of HER2 Trastuzumab uses multiple mechanisms to interfere with HER2 downstream Trastuzumab deruxtecan is an effective new treatment for patients with HER2-positive metastatic breast cancer who have been previously treated